Kluwer Patent Blog

Lundbeck v. Generics, Court of Appeal Civil Division (House of Lords of England and Wales), 25 February 2009

Brian Cordery (Bristows) · Wednesday, February 25th, 2009 · Landmark European Patent Cases

The patent in suit contains claims for the (+)enantiomer of citalopram and a method for its resolution from the racemate (the diol method). The Defendants appealed a decision of the Court of Appeal arguing that the patent was insufficient because it effectively claimed the (+)enantiomer made by any method whereas the specification only disclosed two ways of making it. Resolution of the (+)enantiomer was a known desirable goal at the priority date of the patent. The Defendants submitted that the only technical contribution was the method of resolution taught (the diol method) and therefore only that process, and not the (+)enantiomer itself, can be claimed. The House of Lords ruled that the product claims protecting the (+)enantiomer were valid. The Law Lords agreed with the Court of Appeal's ruling that the (+)enantiomer could be protected by product claims even though the only inventive aspect of the patent was the process of making it.

The full summary of this case has been posted on Kluwer IP Law.

Kluwer IP Law

The **2022 Future Ready Lawyer survey** showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how Kluwer IP Law can support you.


1

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe here.

79% of the lawyers think that the importance of legal technology will increase for next year.

Drive change with Kluwer IP Law. The master resource for Intellectual Property rights and registration.





2022 SURVEY REPORT The Wolters Kluwer Future Ready Lawyer Leading change

This entry was posted on Wednesday, February 25th, 2009 at 8:40 am and is filed under Biologics, Case Law, Sufficiency of disclosure, United Kingdom, Validity

You can follow any responses to this entry through the Comments (RSS) feed. Both comments and pings are currently closed.